EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Brain activation and connectivity after 2–3 weeks of escitalopram administration in anxiety disorders: A randomised trial

Paulina B Lukow, Millie Lowther, Alexandra C Pike, Yumeya Yamamori, Alice V Chavanne, Siobhan Gormley, Jessica Aylward, Carlos Escalante Vera, Tayla McCloud, Talya Goble, Julia Rodriguez-Sanchez, Ella W Tuominen und 3 weitere

Journal of Affective Disorders · 2026

DOI: 10.1016/j.jad.2025.120682 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2026. Verfasst von Paulina B Lukow und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cognitive Neuroscience, Alexandra House, 17-19 Queen Square, WC1N 3AZ, London, UK. Electronic address: p.lukow@ucl.ac.uk. Hauptthemen laut MEDLINE: Anxiety Disorders, Selective Serotonin Reuptake Inhibitors, Escitalopram, Amygdala. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Research and Innovation Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the extensive use of selective serotonin reuptake inhibitors (SSRIs) for anxiety treatment worldwide, their neural mechanism of action remains poorly understood. Based on a systematic line of experimental medicine studies from our laboratory, we posited that SSRI-mediated anxiolysis may be driven by a sustained reduction in positive coupling between the dorsomedial cortex and amygdala in anxious individuals. We conducted a randomised, double-blind, placebo-controlled study investigating amygdala-dorsomedial cortex activation and connectivity during emotion processing after 2-3-week SSRI administration in anxious individuals (ANX) compared to healthy controls (HC). The baseline analysis included 96 HC and 45 ANX participants. The follow-up analysis included 86 HC (placebo n = 40, 73 % female, SSRI n = 46, 74 % female) and 42 ANX participants (placebo n = 22, 86 % female, SSRI n = 20, 80 % female). Consistent with predictions, 2-3 weeks of escitalopram administration altered bilateral amygdala connectivity with the dorsomedial cortex during emotional face processing in people with anxiety disorders compared to healthy controls. However, the effect was in the opposite direction to predicted - positive coupling increased following SSRI in the patient group (right amygdala: ANX-SSRI vs HC-SSRI t = 2.4, p = 0.02; left amygdala: ANX-SSRI vs HC-SSRI t = 2.6, p = 0.01). A follow-up sensitivity analysis confirmed this to be a bilateral effect. These findings suggest that our simple hypothesis of SSRIs inducing a reduction in amygdala-dorsomedial cortex connectivity is incorrect, and the associated brain connectivity may instead increase in the initial weeks of drug administration. The study is registered as a clinical trial at https://www.clinicaltrials.gov. Its clinical trial name is: 'The Effect of SSRIs on Threat of Shock Potentiated Neural Circuitry', number: NCT07074652, URL: https://www.clinicaltrials.gov/study/NCT07074652.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anxiety DisordersSelective Serotonin Reuptake InhibitorsEscitalopramAmygdalaCerebral CortexCitalopramHumansFemaleDouble-Blind MethodAdultMagnetic Resonance ImagingMaleYoung AdultEmotionsNeural Pathways

Stichwörter der Autor:innen

ActivationAnxietyConnectivityEmotionEscitalopramSelective serotonin reuptake inhibitor

Substanzen

Selective Serotonin Reuptake InhibitorsEscitalopramCitalopram

Autor:innen und Institutionen

  • Institute of Cognitive Neuroscience, Alexandra House, 17-19 Queen Square, WC1N 3AZ, London, UK. Electronic address: p.lukow@ucl.ac.uk.
  • Institute of Cognitive Neuroscience, Alexandra House, 17-19 Queen Square, WC1N 3AZ, London, UK; Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, 15 Chaucer Road, CB2 7EF, UK.
  • Institute of Cognitive Neuroscience, Alexandra House, 17-19 Queen Square, WC1N 3AZ, London, UK; Department of Psychology, Institute of Mental Health Research York & York Biomedical Research Institute, University of York…
  • Institute of Cognitive Neuroscience, Alexandra House, 17-19 Queen Square, WC1N 3AZ, London, UK.
  • Institute of Cognitive Neuroscience, Alexandra House, 17-19 Queen Square, WC1N 3AZ, London, UK; Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale, INSERM U1299 "Trajectoires développemen…
  • Shu Chien-Gene Lay Department of Bioengineering, University of California San Diego, 9500 Gilman Drive, Mail Code 0433, La Jolla, CA, 92093-0433, United States of America.

Förderung

  • UK Research and Innovation Medical Research Council

Zitieren

APA

Lukow, P. B., Lowther, M., Pike, A. C., Yamamori, Y., Chavanne, A. V., Gormley, S., Aylward, J., Vera, C. E., McCloud, T., Goble, T., Rodriguez-Sanchez, J., Tuominen, E. W., Buehler, S. K., Kirk, P., & Robinson, O. J. (2026). Brain activation and connectivity after 2–3 weeks of escitalopram administration in anxiety disorders: A randomised trial. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.120682

Vancouver

Lukow PB, Lowther M, Pike AC, Yamamori Y, Chavanne AV, Gormley S, et al. Brain activation and connectivity after 2–3 weeks of escitalopram administration in anxiety disorders: A randomised trial. Journal of Affective Disorders. 2026. doi:10.1016/j.jad.2025.120682

BibTeX
@article{Lukow2026,
  author = {Lukow, Paulina B and Lowther, Millie and Pike, Alexandra C and Yamamori, Yumeya and Chavanne, Alice V and Gormley, Siobhan and Aylward, Jessica and Vera, Carlos Escalante and McCloud, Tayla and Goble, Talya and Rodriguez-Sanchez, Julia and Tuominen, Ella W and Buehler, Sarah K and Kirk, Peter and Robinson, Oliver J},
  title = {Brain activation and connectivity after 2–3 weeks of escitalopram administration in anxiety disorders: A randomised trial},
  journal = {Journal of Affective Disorders},
  year = {2026},
  doi = {10.1016/j.jad.2025.120682}
}
Kostenlos starten →